Therapeutic Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Prevention of Organ Injuries Induced by Traumatic Hemorrhagic Shock
Open Access
- 29 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Abstract
Severe trauma is the principal cause of death among young people worldwide. Hemorrhagic shock is the leading cause of death after severe trauma. Traumatic hemorrhagic shock (THS) is a complex phenomenon associating an absolute hypovolemia secondary to a sudden and significant extravascular blood loss, tissue injury, and, eventually, hypoxemia. These phenomena are responsible of secondary injuries such as coagulopathy, endotheliopathy, microcirculation failure, inflammation, and immune activation. Collectively, these dysfunctions lead to secondary organ failures and multi-organ failure (MOF). The development of MOF after severe trauma is one of the leading causes of morbidity and mortality, where immunological dysfunction plays a central role. Damage-associated molecular patterns induce an early and exaggerated activation of innate immunity and a suppression of adaptive immunity. Severe complications are associated with a prolonged and dysregulated immune–inflammatory state. The current challenge in the management of THS patients is preventing organ injury, which currently has no etiological treatment available. Modulating the immune response is a potential therapeutic strategy for preventing the complications of THS. Mesenchymal stromal cells (MSCs) are multipotent cells found in a large number of adult tissues and used in clinical practice as therapeutic agents for immunomodulation and tissue repair. There is growing evidence that their efficiency is mainly attributed to the secretion of a wide range of bioactive molecules and extracellular vesicles (EVs). Indeed, different experimental studies revealed that MSC-derived EVs (MSC-EVs) could modulate local and systemic deleterious immune response. Therefore, these new cell-free therapeutic products, easily stored and available immediately, represent a tremendous opportunity in the emergency context of shock. In this review, the pathophysiological environment of THS and, in particular, the crosstalk between the immune system and organ function are described. The potential therapeutic benefits of MSCs or their EVs in treating THS are discussed based on the current knowledge. Understanding the key mechanisms of immune deregulation leading to organ damage is a crucial element in order to optimize the preparation of EVs and potentiate their therapeutic effect.Keywords
This publication has 309 references indexed in Scilit:
- Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in miceHepatology, 2011
- Isolated blunt chest injury leads to transient activation of circulating neutrophilsEuropean Journal of Trauma and Emergency Surgery, 2010
- A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine releaseProceedings of the National Academy of Sciences, 2010
- Diagnosis-Dependent Relationships between Cytokine Levels and Survival in Patients Admitted for Surgical Critical CareJournal of the American College of Surgeons, 2010
- Circulating mitochondrial DAMPs cause inflammatory responses to injuryNature, 2010
- Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophagesExperimental Hematology, 2009
- Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injuryKidney International, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- The mitochondrial permeability transition pore and ischemia-reperfusion injuryBasic Research in Cardiology, 2009
- Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine, 2008